The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...

The US Food and Drug Administration (FDA) has approved a label expansion for Novartis’s Kisqali (ribociclib), allowing it to be used as an add-on therapy in early breast cancer patients. The therapy ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination ...

The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor as adjuvant treatment for adults with hormone receptor (HR)-positive, ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhi ...

A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...

Ribociclib (brand name Kisqali) is a CDK4/6 inhibitor, a type of drug that targets specific enzymes — including the protein CDK6 — to stop cancer cells from growing. In the study, which was ...

Ribociclib (brand name Kisqali) is a CDK4/6 inhibitor, a type of drug that targets specific enzymes — including the protein CDK6 — to stop cancer cells from growing. In the study, which was published ...